UK based drug delivery specialist, Q Chip, launches ocular spin-out, OpsiRx Pharmaceuticals, reports significant progress and appoints new Chairman

Q Chip's Board made the following announcement today:

·         Q Chip has launched OpsiRx Pharmaceuticals Ltd ("OpsiRx"), the ophthalmology company developing products addressing unmet clinical needs including in uveitis and glaucoma. 

·         The Company has successfully demonstrated sterile manufacturing for its proprietary technology. Achievement of this milestone now enables production of material for clinical studies. The Independent clinical advisory board to OpsiRx has identified sustained release delivery direct to the eye as the ideal application.

·         The company is also pleased to announce that Simon Turton has joined as Chairman. Formerly Head of European Healthcare Investments at Warburg Pincus, Dr Turton brings a wealth of experience in pharmaceuticals including in ophthalmology.

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.